Review



vaccine effectiveness against infection following booster dose  (Pfizer Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Pfizer Inc vaccine effectiveness against infection following booster dose
    Vaccine Effectiveness Against Infection Following Booster Dose, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vaccine+booster+dose/vaccine+effectiveness+against+infection+following+booster+dose/pmc11208616-11-18-22
    Average 90 stars, based on 1 article reviews
    vaccine effectiveness against infection following booster dose - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Plaque Reduction Neutralization Test:

    Article Title: Heterogeneity of humoral response patterns in mildly symptomatic, non-hospitalized COVID-19 patients: A one-year longitudinal study
    Article Snippet: .. We did not calculate the NPI after Pfizer’s vaccine booster dose as the PRNT 50 was above the measurable threshold. ..

    other:

    Article Title: Heterogeneity of humoral response patterns in mildly symptomatic, non-hospitalized COVID-19 patients: A one-year longitudinal study
    Article Snippet: Approximately eight months after Coronavac’s second dose, anti-S1 IgG dropped to the lowest levels, but antibody levels were quickly boosted after the Pfizer vaccine booster dose; anti-NS1 antibody levels raised from an average index of 2.1–10.9, representing a 519% increase.



    Similar Products

    updated (bivalent) covid-19 vaccine booster dose  (Novavax Inc)
    90
    Novavax Inc updated (bivalent) covid-19 vaccine booster dose
    Timeline of COVID-19 vaccine policy decisions.
    Updated (Bivalent) Covid 19 Vaccine Booster Dose, supplied by Novavax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vaccine+booster+dose/updated++bivalent++covid+19+vaccine+booster+dose/pmc11893158-42-17-4
    Average 90 stars, based on 1 article reviews
    updated (bivalent) covid-19 vaccine booster dose - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    covid-19 vaccine booster dose  (Novavax Inc)
    90
    Novavax Inc covid-19 vaccine booster dose
    Timeline of COVID-19 vaccine policy decisions.
    Covid 19 Vaccine Booster Dose, supplied by Novavax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vaccine+booster+dose/novavax+covid+19+vaccine/pmc11893158-207-2-1
    Average 90 stars, based on 1 article reviews
    covid-19 vaccine booster dose - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    ipol (sanofi pasteur) inactivated polio vaccine booster dose  (Sanofi)
    90
    Sanofi ipol (sanofi pasteur) inactivated polio vaccine booster dose
    List of completed clinical trials for microneedle-based transdermal vaccination.
    Ipol (Sanofi Pasteur) Inactivated Polio Vaccine Booster Dose, supplied by Sanofi, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vaccine+booster+dose/multi+dose+vaccine+vials+ipol/pmc11843882-23-15-16
    Average 90 stars, based on 1 article reviews
    ipol (sanofi pasteur) inactivated polio vaccine booster dose - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    ba.1 bivalent mrna vaccine booster dose  (Moderna)
    90
    Moderna ba.1 bivalent mrna vaccine booster dose
    Plasma neutralizing activity was measured using a live virus neutralization assay against SARS-CoV-2 Omicron <t>BA.1</t> ( A – E ) and XBB.1.5 ( F – J ) variants. Pre-booster ( A and F ) and post-booster day-14 (D14) ( D and I ) and day-84 (D84) ( E and J ) neutralizing antibody responses were compared between the delayed (blue/purple diamonds, n = 24) and immediate arms (pink triangles, n = 24) at the respective sampling time points. Line graphs describe the kinetics of plasma neutralization activity of the delayed ( B and G ) and immediate ( C and H ) arms after receiving the bivalent booster. Numbers above each time point describe the respective median neutralization IC 50 against each viral variant. Dotted lines depict the detection threshold for the assay (neutralization IC 50 = 20). Dark purple diamonds and lines show the antibody responses of the 3 individuals who received the BA.5 bivalent booster in the delayed arm of the study. Saliva neutralizing activity against ancestral SARS-CoV-2 was measured using the sVNT (Genscript). Pre-booster ( K ) and post-booster day-14 ( N ) neutralizing antibody responses were compared between the delayed (purple diamonds, n = 18) and immediate arms (pink triangles, n = 19), respectively. Line graphs describe the change in saliva neutralization activity following the bivalent booster ( L and M ). Numbers describe the percentage of surrogate neutralization observed at each time point. Dotted lines depict the sVNT cutoff for neutralizing activity (30%). Statistical significance was calculated between cohorts and time points using the 2-tailed Mann-Whitney U test or the Kruskal-Wallis test followed by Dunn’s multiple-comparison test. Paired saliva analysis (day 0 vs. day 14) was performed using the Wilcoxon matched-pairs, signed-rank test. Experiments were performed in duplicate. Graphs are displayed as the median, and where significant, P values are reported (** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001).
    Ba.1 Bivalent Mrna Vaccine Booster Dose, supplied by Moderna, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vaccine+booster+dose/mrna+1273/pmc11364387-122-13-12
    Average 90 stars, based on 1 article reviews
    ba.1 bivalent mrna vaccine booster dose - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    vaccine effectiveness against infection following booster dose  (Pfizer Inc)
    90
    Pfizer Inc vaccine effectiveness against infection following booster dose
    Plasma neutralizing activity was measured using a live virus neutralization assay against SARS-CoV-2 Omicron <t>BA.1</t> ( A – E ) and XBB.1.5 ( F – J ) variants. Pre-booster ( A and F ) and post-booster day-14 (D14) ( D and I ) and day-84 (D84) ( E and J ) neutralizing antibody responses were compared between the delayed (blue/purple diamonds, n = 24) and immediate arms (pink triangles, n = 24) at the respective sampling time points. Line graphs describe the kinetics of plasma neutralization activity of the delayed ( B and G ) and immediate ( C and H ) arms after receiving the bivalent booster. Numbers above each time point describe the respective median neutralization IC 50 against each viral variant. Dotted lines depict the detection threshold for the assay (neutralization IC 50 = 20). Dark purple diamonds and lines show the antibody responses of the 3 individuals who received the BA.5 bivalent booster in the delayed arm of the study. Saliva neutralizing activity against ancestral SARS-CoV-2 was measured using the sVNT (Genscript). Pre-booster ( K ) and post-booster day-14 ( N ) neutralizing antibody responses were compared between the delayed (purple diamonds, n = 18) and immediate arms (pink triangles, n = 19), respectively. Line graphs describe the change in saliva neutralization activity following the bivalent booster ( L and M ). Numbers describe the percentage of surrogate neutralization observed at each time point. Dotted lines depict the sVNT cutoff for neutralizing activity (30%). Statistical significance was calculated between cohorts and time points using the 2-tailed Mann-Whitney U test or the Kruskal-Wallis test followed by Dunn’s multiple-comparison test. Paired saliva analysis (day 0 vs. day 14) was performed using the Wilcoxon matched-pairs, signed-rank test. Experiments were performed in duplicate. Graphs are displayed as the median, and where significant, P values are reported (** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001).
    Vaccine Effectiveness Against Infection Following Booster Dose, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vaccine+booster+dose/vaccine+effectiveness+against+infection+following+booster+dose/pmc11208616-11-18-22
    Average 90 stars, based on 1 article reviews
    vaccine effectiveness against infection following booster dose - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    covid-19 vaccine booster dose  (Janssen)
    90
    Janssen covid-19 vaccine booster dose
    Plasma neutralizing activity was measured using a live virus neutralization assay against SARS-CoV-2 Omicron <t>BA.1</t> ( A – E ) and XBB.1.5 ( F – J ) variants. Pre-booster ( A and F ) and post-booster day-14 (D14) ( D and I ) and day-84 (D84) ( E and J ) neutralizing antibody responses were compared between the delayed (blue/purple diamonds, n = 24) and immediate arms (pink triangles, n = 24) at the respective sampling time points. Line graphs describe the kinetics of plasma neutralization activity of the delayed ( B and G ) and immediate ( C and H ) arms after receiving the bivalent booster. Numbers above each time point describe the respective median neutralization IC 50 against each viral variant. Dotted lines depict the detection threshold for the assay (neutralization IC 50 = 20). Dark purple diamonds and lines show the antibody responses of the 3 individuals who received the BA.5 bivalent booster in the delayed arm of the study. Saliva neutralizing activity against ancestral SARS-CoV-2 was measured using the sVNT (Genscript). Pre-booster ( K ) and post-booster day-14 ( N ) neutralizing antibody responses were compared between the delayed (purple diamonds, n = 18) and immediate arms (pink triangles, n = 19), respectively. Line graphs describe the change in saliva neutralization activity following the bivalent booster ( L and M ). Numbers describe the percentage of surrogate neutralization observed at each time point. Dotted lines depict the sVNT cutoff for neutralizing activity (30%). Statistical significance was calculated between cohorts and time points using the 2-tailed Mann-Whitney U test or the Kruskal-Wallis test followed by Dunn’s multiple-comparison test. Paired saliva analysis (day 0 vs. day 14) was performed using the Wilcoxon matched-pairs, signed-rank test. Experiments were performed in duplicate. Graphs are displayed as the median, and where significant, P values are reported (** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001).
    Covid 19 Vaccine Booster Dose, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vaccine+booster+dose/covid+19+booster+vaccination/pmc11068153-294-7-22
    Average 90 stars, based on 1 article reviews
    covid-19 vaccine booster dose - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    vaccine booster dose  (Pfizer Inc)
    90
    Pfizer Inc vaccine booster dose
    Plasma neutralizing activity was measured using a live virus neutralization assay against SARS-CoV-2 Omicron <t>BA.1</t> ( A – E ) and XBB.1.5 ( F – J ) variants. Pre-booster ( A and F ) and post-booster day-14 (D14) ( D and I ) and day-84 (D84) ( E and J ) neutralizing antibody responses were compared between the delayed (blue/purple diamonds, n = 24) and immediate arms (pink triangles, n = 24) at the respective sampling time points. Line graphs describe the kinetics of plasma neutralization activity of the delayed ( B and G ) and immediate ( C and H ) arms after receiving the bivalent booster. Numbers above each time point describe the respective median neutralization IC 50 against each viral variant. Dotted lines depict the detection threshold for the assay (neutralization IC 50 = 20). Dark purple diamonds and lines show the antibody responses of the 3 individuals who received the BA.5 bivalent booster in the delayed arm of the study. Saliva neutralizing activity against ancestral SARS-CoV-2 was measured using the sVNT (Genscript). Pre-booster ( K ) and post-booster day-14 ( N ) neutralizing antibody responses were compared between the delayed (purple diamonds, n = 18) and immediate arms (pink triangles, n = 19), respectively. Line graphs describe the change in saliva neutralization activity following the bivalent booster ( L and M ). Numbers describe the percentage of surrogate neutralization observed at each time point. Dotted lines depict the sVNT cutoff for neutralizing activity (30%). Statistical significance was calculated between cohorts and time points using the 2-tailed Mann-Whitney U test or the Kruskal-Wallis test followed by Dunn’s multiple-comparison test. Paired saliva analysis (day 0 vs. day 14) was performed using the Wilcoxon matched-pairs, signed-rank test. Experiments were performed in duplicate. Graphs are displayed as the median, and where significant, P values are reported (** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001).
    Vaccine Booster Dose, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vaccine+booster+dose/vaccine+booster+dose/pmc11144042-110-36-35
    Average 90 stars, based on 1 article reviews
    vaccine booster dose - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Timeline of COVID-19 vaccine policy decisions.

    Journal: Vaccine

    Article Title: Development of COVID-19 vaccine policy — United States, 2020–2023 ☆

    doi: 10.1016/j.vaccine.2023.12.022

    Figure Lengend Snippet: Timeline of COVID-19 vaccine policy decisions.

    Article Snippet: October 19, 2022 , Novavax , ≥ 18 years , Persons unwilling or unable to receive an updated (bivalent) COVID-19 vaccine booster dose and not received a previous booster dose , Single booster dose.

    Techniques: Vaccines, Transmission Assay

    Timeline of COVID-19 vaccine policy decisions.

    Journal: Vaccine

    Article Title: Development of COVID-19 vaccine policy — United States, 2020–2023 ☆

    doi: 10.1016/j.vaccine.2023.12.022

    Figure Lengend Snippet: Timeline of COVID-19 vaccine policy decisions.

    Article Snippet: A Novavax COVID-19 Vaccine booster dose was recommended for people ages ≥ 18 years who were unable or unwilling to receive an updated (bivalent) Pfizer or Moderna COVID-19 booster and had not received a previous booster dose[ ].

    Techniques: Vaccines, Transmission Assay

    List of completed clinical trials for microneedle-based transdermal vaccination.

    Journal: Medicines

    Article Title: Beyond the Needle: Innovative Microneedle-Based Transdermal Vaccination

    doi: 10.3390/medicines12010004

    Figure Lengend Snippet: List of completed clinical trials for microneedle-based transdermal vaccination.

    Article Snippet: NCT01686503 , 2 , Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects , Drug: IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose , NanoPass MicronJet 600 ® microneedles device , Polio Immunity , Eastern Virginia Medical School NanoPass Technologies Ltd..

    Techniques: Clinical Proteomics, Immunopeptidomics, Vaccines, Control, Saline, Injection, Infection, Cream, Transplantation Assay, Formulation, Selection

    Plasma neutralizing activity was measured using a live virus neutralization assay against SARS-CoV-2 Omicron BA.1 ( A – E ) and XBB.1.5 ( F – J ) variants. Pre-booster ( A and F ) and post-booster day-14 (D14) ( D and I ) and day-84 (D84) ( E and J ) neutralizing antibody responses were compared between the delayed (blue/purple diamonds, n = 24) and immediate arms (pink triangles, n = 24) at the respective sampling time points. Line graphs describe the kinetics of plasma neutralization activity of the delayed ( B and G ) and immediate ( C and H ) arms after receiving the bivalent booster. Numbers above each time point describe the respective median neutralization IC 50 against each viral variant. Dotted lines depict the detection threshold for the assay (neutralization IC 50 = 20). Dark purple diamonds and lines show the antibody responses of the 3 individuals who received the BA.5 bivalent booster in the delayed arm of the study. Saliva neutralizing activity against ancestral SARS-CoV-2 was measured using the sVNT (Genscript). Pre-booster ( K ) and post-booster day-14 ( N ) neutralizing antibody responses were compared between the delayed (purple diamonds, n = 18) and immediate arms (pink triangles, n = 19), respectively. Line graphs describe the change in saliva neutralization activity following the bivalent booster ( L and M ). Numbers describe the percentage of surrogate neutralization observed at each time point. Dotted lines depict the sVNT cutoff for neutralizing activity (30%). Statistical significance was calculated between cohorts and time points using the 2-tailed Mann-Whitney U test or the Kruskal-Wallis test followed by Dunn’s multiple-comparison test. Paired saliva analysis (day 0 vs. day 14) was performed using the Wilcoxon matched-pairs, signed-rank test. Experiments were performed in duplicate. Graphs are displayed as the median, and where significant, P values are reported (** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001).

    Journal: The Journal of Clinical Investigation

    Article Title: Randomized controlled trial reveals no benefit to a 3-month delay in COVID-19 mRNA booster vaccine

    doi: 10.1172/JCI181244

    Figure Lengend Snippet: Plasma neutralizing activity was measured using a live virus neutralization assay against SARS-CoV-2 Omicron BA.1 ( A – E ) and XBB.1.5 ( F – J ) variants. Pre-booster ( A and F ) and post-booster day-14 (D14) ( D and I ) and day-84 (D84) ( E and J ) neutralizing antibody responses were compared between the delayed (blue/purple diamonds, n = 24) and immediate arms (pink triangles, n = 24) at the respective sampling time points. Line graphs describe the kinetics of plasma neutralization activity of the delayed ( B and G ) and immediate ( C and H ) arms after receiving the bivalent booster. Numbers above each time point describe the respective median neutralization IC 50 against each viral variant. Dotted lines depict the detection threshold for the assay (neutralization IC 50 = 20). Dark purple diamonds and lines show the antibody responses of the 3 individuals who received the BA.5 bivalent booster in the delayed arm of the study. Saliva neutralizing activity against ancestral SARS-CoV-2 was measured using the sVNT (Genscript). Pre-booster ( K ) and post-booster day-14 ( N ) neutralizing antibody responses were compared between the delayed (purple diamonds, n = 18) and immediate arms (pink triangles, n = 19), respectively. Line graphs describe the change in saliva neutralization activity following the bivalent booster ( L and M ). Numbers describe the percentage of surrogate neutralization observed at each time point. Dotted lines depict the sVNT cutoff for neutralizing activity (30%). Statistical significance was calculated between cohorts and time points using the 2-tailed Mann-Whitney U test or the Kruskal-Wallis test followed by Dunn’s multiple-comparison test. Paired saliva analysis (day 0 vs. day 14) was performed using the Wilcoxon matched-pairs, signed-rank test. Experiments were performed in duplicate. Graphs are displayed as the median, and where significant, P values are reported (** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001).

    Article Snippet: Participants were recruited in Melbourne, Australia, and were randomized to receive a Moderna BA.1 bivalent mRNA vaccine booster dose (0.5 mL) administered intramuscularly upon enrollment (immediate arm) or 3 months later (delayed arm).

    Techniques: Activity Assay, Virus, Neutralization, Sampling, Variant Assay, MANN-WHITNEY, Comparison